

I. PERSONAL DETAILS

Current as of August 2014

Name: Ronan Swords

Nationality: Irish

Contact Details: Office - (305) 243 3084,

Present Position: Assistant Professor of Medicine, Leukemia Program, Sylvester Comprehensive Cancer, University of Miami Miller School of Medicine.

Citizenship: Irish

Visa Status: Permanent US resident

Licensure: Texas (P1145), Florida (MFC1686)

II. HIGHER EDUCATION

2000: National University of Ireland Galway (NUIG). MD (Hons).

2002: Medical internship/residency. Royal College of Physicians of Ireland, member (MRCPI)

2008: Hematology Fellowship. Royal College of Pathologists London, fellow (FRCPath)

2009: Advanced drug development fellowship, Cancer Therapy and Research Center, University of Texas Health Science Center San Antonio (UTHSCSA)

2011: Royal College of Physicians of Ireland, fellow (FRCPI)

2012: Post doctoral Thesis, National University of Ireland Galway (NUIG)/University of Texas Health Science Center San Antonio (UTHSCSA), PhD

III. EXPERIENCE

ACADEMIC APPOINTMENTS

2009-12: Assistant Professor of Medicine, University of Texas Health Science Center, San Antonio

2012-present: Sylvester Comprehensive Cancer Center, University of Miami.

ADMINISTRATIVE/COMMITTEE APPOINTMENTS

University of Texas Health Science Center, San Antonio (UTHSCSA).

Committee Service: Blood and Tissue Utilization Committee (member)
Institutional Protocol Review Committee (member)
Clinical Trials Accrual Committee (chairman)
Institutional Data and Safety Monitoring Committee (member)
Institutional Protocol Review Committee (member)

Administrative: UTHSCSA clinical operations, Christus Santa Rosa Hospital (director)

University of Miami, Sylvester Comprehensive Cancer Center (SCCC).

Committee Service: Phase I Site Disease Group (member)
Institutional Protocol Review Committee (member)
Clinical Research Services Advisory Committee (co- chair)
Lymphoma, Leukemia and Myeloma Site Disease Group (co-leader)
Hematologic Malignancies Program (member)
Cancer Center (member)
Experimental Therapeutics Program (member)

IV. PUBLICATIONS

1.Manuscripts.

1. Stein BL, **Swords R**, Hochhaus A, Giles F. Novel myelofibrosis treatment strategies: potential partners for combination therapies. *Leukemia*. 2014 Jun 3, Epub ahead of print.
2. Giles FJ, Krawczyk J, O'Dwyer M, **Swords R**, Freeman C. The role of inflammation in leukaemia. *Adv Exp Med Biol*. 2014;816:335-60
3. O'Dwyer ME, **Swords R**, Nagler A, McMullin MF, le Coutre PD, Langabeer SE, Alvarez-Iglesias A, Fan H, Woodman RC, Giles FJ, Conneally E. Nilotinib 300mg BID as frontline treatment of CML: Prospective analysis of the Xpert BCR-ABL Monitor system and significance of 3-month molecular response. *Leuk Res*. 2014 Mar;38(3):310-5
4. Krawczyk J, Keane N, **Swords R**, O'Dwyer M, Freeman CL, Giles FJ. Perifosine--a new option in treatment of acute myeloid leukemia? *Expert Opin Investig Drugs*. 2013 Oct;22(10):1315-27.
5. Krawczyk J, Keane N, Freeman CL, **Swords R**, O'Dwyer M, Files FL. 5-Azacytadine for the treatment of myelodysplastic syndromes. *Expert Opin Pharmacother*. 2013 April 27.
6. Freeman C, Keane N, **Swords R**, Giles F. Vosaroxin: a new valuable tool with the potential to replace anthracyclines in the treatment of AML? *Expert Opin Pharmacother*. 2013 Jul;14(10):1417-27.
7. Pimentel A, Velez M, Barahona LJ, **Swords R**, Lekakis L. New prospects for drug development: the hedgehog pathway revealed. *Focus on hematologic malignancies. Future Oncol*. 2013 May;9(5):681-97.
8. Keane N, Freeman C, **Swords R**, Giles FJ. Elacytarabine: lipid vector technology under investigation in acute myeloid leukemia. *Expert Rev Hematol*. 2013 Feb;6(1):9-24.
9. **Swords R**, Santini V. In elderly patients with AML, which patients should be considered fit or unfit for standard induction therapy? *Hematology Am Soc Hematol Educ Program*. 2012;2012:74-5.
10. Keane N, Freeman C, **Swords R**, Giles FJ. EPHA3 as a novel therapeutic target in the hematological malignancies. *Expert Rev Hematol*. 2012 Jun;5(3):325-40.
11. Giles FJ, **Swords RT**, Nagler A, Hochhaus A, Ottmann OG, Rizzieri DA, Talpaz M, Clark J, Watson P, Xiao A, Zhao B, Bergstrom D, Le Coutre PD, Freedman SJ, Cortes JE. MK-0457, an Aurora kinase and BCR-ABL inhibitor, is active in patients with BCR-ABL T3151 leukemia. *Leukemia*. 2013 Jan;27(1):113-7.
12. **Swords R**, Freeman C, Giles F. Targeting the FMS-like tyrosine kinase 3 in acute myeloid leukemia. *Leukemia*. 2012 Oct;26(10):2176-85.
13. Giles F, Mahon FX, Gjertsen B, **Swords R**, Labar B, Turkina A, Rosti G. Developmental Therapeutics Consortium report on study design effects on trial outcomes in chronic myeloid leukaemia. *Eur J Clin Invest*. 2012 Sep;42(9):1016-26.
14. Alvarado Y, Giles FJ, **Swords RT**. The PIM kinases in hematological cancers. *Expert Rev Hematol*. 2012 Feb;5(1):81-96.
15. Freeman CL, **Swords R**, Giles FJ. Amonafide: a future in treatment of resistant and secondary acute myeloid leukemia? *Expert Rev Hematol*. 2012 Feb;5(1):17-26.
16. Giles F, Rizzieri D, Ravandi F, **Swords R**, Jacobsen TF, O'Brien S. Elacytarabine, a novel 5'-elaidic acid derivative of cytarabine, and idarubicin combination is active in refractory acute myeloid leukemia. *LeukRes*. 2012 Apr;36(4):e71-3.
17. Miller LJ, Philbeck TE, Montez DF, Puga TA, Brodie KE, Cohen SC, Spadaccini C, **Swords R**, Brenner AJ. Powered bone marrow biopsy procedures produce larger core specimens, with less pain, in less time than with standard manual devices. *Hematol Rep*. 2011 Jan 13;3(1):e8.
18. **Swords R**, Kelly K, Carew J, Nawrocki S, Mahalingam D, Sarantopoulos J, Bearss D, Giles F. The Pim kinases: new targets for drug development. *Curr Drug Targets*. 2011 Dec;12(14):2059-66.
19. **Swords RT**, Dezube BJ, Medeiros BC. Personalized medicine for acute myelogenous leukemia--at the entrance gate. *Am J Hematol*. 2011 Aug;86(8):631-2.
20. **Swords RT**, Anguita J, Higgins RA, Yunes AC, Naski M, Padmanabhan S, Kelly KR, Mahalingam D, Philbeck T, Miller L, Puga TA, Giles FJ, Kinney MC, Brenner AJ. A

- prospective randomised study of a rotary powered device (OnControl) for bone marrow aspiration and biopsy. *J Clin Pathol*. 2011 Sep;64(9):809-13.
21. Burke AC, **Swords RT**, Kelly K, Giles FJ. Current status of agents active against the T315l chronic myeloid leukemia phenotype. *Expert Opin Emerg Drugs*. 2011 Mar;16(1):85-103.
 22. Alvarado Y, **Swords R**, Kelly KR, Giles FJ. Clinical activity of laromustine (Onrigin™) in hematologic malignancies. *Expert Rev Hematol*. 2009 Oct;2(5):481-8.
 23. **Swords RT**, Kelly KR, Cohen SC, Miller LJ, Philbeck TE, Hacker SO, Spadaccini CJ, Giles FJ, Brenner AJ. Rotary powered device for bone marrow aspiration and biopsy yields excellent specimens quickly and efficiently. *J Clin Pathol*. 2010 Jun;63(6):562-5.
 24. Aine Carol Burke, **Ronan Swords**, Kevin Kelly, Francis Giles. Current status of agents active against the T315l chronic myeloid leukemia phenotype. *Expert Opin. Emerging Drugs* (2010) 16(1):85-103.
 25. Meng Wang, Bruno Madeiros, Harry Erba, Dan DeAngelo, Frank Giles, **Ronan Swords**. Targeting Protein Neddylation : A Novel Therapeutic Strategy for the Treatment of Cancer. *Expert Opinion on Therapeutic Targets* 2011 Mar;15(3):253-64.
 26. Ting Lu, **Ronan Swords**, Francis Giles, Kevin Kelly. Nilotinib: A review of its use in drug resistant chronic myeloid leukemia. *Clinical Medicine Insights: Therapeutics* 2010;2 841-848
 27. Kelly K, **Swords R**, Mahalingam D, Giles FJ. Optimizing outcomes in patients with chronic myeloid leukemia in chronic phase: comparative safety profiles of newer agents. *Leuk Lymphoma*. 2010 Aug;51(8):1399-413.
 28. Bansal H, Bansal S, Rao M, Foley KP, Sang J, Proia DA, Blackman RK, Ying W, Barsoum J, Baer MR, Kelly K, **Swords R**, Tomlinson G, Battiwalla M, Giles FJ, Lee KP, Padmanabhan S. Heat shock protein 90 regulates the expression of Wilms' tumor1 protein in myeloid leukemias. *Blood*. 2010 Jul 22.
 29. **Swords RT**, Kelly KR, Cohen SC, Miller LJ, Philbeck TE, Hacker SO, Spadaccini CJ, Giles FJ, Brenner AJ. Rotary powered device for bone marrow aspiration and biopsy yields excellent specimens quickly and efficiently. *J Clin Pathol*. 2010 Jun;63(6):562-5.
 30. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. *N Engl J Med*. 2010 Jun 17;362(24):2251-9. F1000 Evaluation by **Ronan Swords** and Francis Giles, July 2010.
 31. **Swords RT**, Kelly KR, Smith PG, Garnsey JJ, Mahalingam D, Medina E, Oberheu K, Padmanabhan S, O'Dwyer M, Nawrocki ST, Giles FJ, Carew JS. Inhibition of NEDD8-activating enzyme: a novel approach for the treatment of acute myeloid leukemia. *Blood*. 2010 May 6;115(18):3796-800.
 32. Cronin CG, **Swords R**, Truong MT, Viswanathan C, Rohren E, Giles FJ, O'Dwyer M, Bruzzi JF. Clinical utility of PET/CT in lymphoma. *AJR Am J Roentgenol*. 2010 Jan;194(1).
 33. Mahalingam D, Medina EC, Esquivel JA 2nd, Espitia CM, Smith S, Oberheu K, **Swords R**, Kelly KR, Mita MM, Mita AC, Carew JS, Giles FJ, Nawrocki ST. Vorinostat enhances the activity of temsirolimus in renal cell carcinoma through suppression of survivin levels. *Clin Cancer Res*. 2010 Jan 1;16(1):141-53.
 34. Nilotinib for the frontline treatment of Ph⁺ chronic myeloid leukemia. *Blood*, 3 December 2009, Vol. 114, No. 24, pp. 4933-493. F1000 Evaluation by **Ronan Swords** and Francis Giles, Nov 2009
 35. Immunosuppression and atypical infections in CML patients treated with dasatinib at 140 mg daily. *Eur J Clin Invest*. 2009 Dec;39(12):1098-109. Epub 2009 Sep 9. F1000 Evaluation by **Ronan Swords** and Francis Giles, Jan 2010.
 36. Cronin CG, Cashell T, Mhuircheartaigh JN, **Swords R**, Murray M, O'Sullivan GJ, O'Keeffe D. Bone biopsy of new suspicious bone lesions in patients with primary carcinoma: prevalence and probability of an alternative diagnosis. *AJR Am J Roentgenol*. 2009 Nov;193(5).
 37. Mahalingam D, Mita A, Sankhala K, **Swords R**, Kelly K, Giles F, Mita MM. Targeting sarcomas: novel biological agents and future perspectives *Curr Drug Targets*. 2009 Oct;10(10):937-49.
 38. **Swords R**, Mahalingam D, O'Dwyer M, Santocanale C, Kelly K, Carew J, Giles F. Cdc7 kinase – A new target for drug development. *Eur J Cancer*. 2010 Jan;46(1):33-40.
 39. Alvarado Y, **Swords R**, Kelly KR., Giles FJ. Clinical Activity of Laromustine (Onrigin™) in Hematologic Malignancies. *Expert Rev Hematol*. 2009 Oct;2(5):481-8.

40. **Swords R**, Mahalingam D, Padmanabhan S, Carew J, Giles F. Nilotinib: optimal therapy for patients with chronic myeloid leukemia and resistance or intolerance to imatinib. *Drug Des Devel Ther.* 2009 Sep 21;3:89-101.
41. Krawczyk J, Ansar N, **Swords R**, Murphy T, Macdonagh B, Meenaghan T, Hayden P, Hayad A, Murray M, O'Dwyer M. Clofarabine in the treatment of poor risk acute myeloid leukemia. *Hematol Oncol.* 2010 Sep;28(3):118-23.
42. Carew JS, Medina EC, Esquivel JA 2nd, Mahalingam D, **Swords R**, Kelly K, Zhang H, Huang P, Mita AC, Mita MM, Giles FJ, Nawrocki ST. Autophagy inhibition enhances vorinostat induced apoptosis via ubiquitinated protein accumulation. *J Cell Mol Med.* 2010 Oct;14(10):2448-59.
43. Mahalingam D, Kelly KR, **Swords RT**, Carew J, Nawrocki ST, Giles F. Emerging Drugs in the treatment of Pancreatic Cancer. *Expert Opin Emerg Drugs.* 2009 Jun;14(2):311-28.
44. O'Dwyer M, Giles FJ, **Swords R**. Class effects of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia. *Leukemia.* 2009 Oct;23(10):1698-707.
45. Mahalingam D, **Swords R**, Carew JS, Nawrocki ST, Bhalla K, Giles FJ. Targeting HSP90 for cancer therapy. *Br J Cancer.* 2009 May 19;100(10):1523-9.
46. Kelly K, **Swords R**, Mahalingam D, Padmanabhan S, Giles FJ. Serosal inflammation (pleural and pericardial effusions) related to tyrosine kinase inhibitors. *Target Oncol.* 2009 Apr;4(2):99-105.
47. Kelly K, **Swords R**, Kilcoyne A, Sankhala K, Mahalingam D, Padmanabhan S, Giles F. Acute lymphoblastic leukemia presenting with avascular necrosis of the elbow. *Leuk Lymphoma.* 2009 Feb;50(2):297-9.
48. **Swords R.**, Kelly K., Giles F. Nilotinib therapy in patients with chronic myeloid leukemia who have failed imatinib. *US Hematology.* 2009 Oct; 2(1): 30-33.
49. **Swords R.**, Mahalingam D., Padmanabhan S., Carew J., Giles F. Nilotinib: optimal therapy for patients with chronic myeloid leukemia and resistance or intolerance to imatinib. *Drug Design, Development and Therapy* 2009;3 89–101
50. Morris PG, **Swords R**, Sukor S, Fortune A, O'Donnell DM, Conneally E. Autoimmune hemolytic anemia associated with ovarian cancer. *J Clin Oncol.* 2008 Oct 20;26(30):4993-5.
51. **Swords R**, O'Rafferty C, Giles F, Browne P. Spurious elevation of the cerebrospinal fluid white cell counts in three patients receiving liposomal cytarabine as part of post-remission therapy. *Leukemia.* 2008 Dec;22(12):2277-8.
52. **Swords R.**, Alvarado Y., Giles F. The current status of biphenotypic leukemia. *Myeloproliferative Disorders in Practice.* 2008;2(2):3-5
53. **Swords R**, Giles F. Troxacitabine in acute leukemia. *Hematology.* 2007 Jun;12(3):219-27.
54. Alvarado Y, Welch MA, **Swords R**, Bruzzi J, Schlette E, Giles FJ. Nelarabine activity in acute biphenotypic leukemia. *Leuk Res.* 2007 Nov;31(11):1600-3.
55. Cronin CG, Lohan DG, **Swords R**, Murray M, Murphy JM, Roche C. Sacral insufficiency fracture complicated by epidural haematoma and cauda equina syndrome in a patient with multiple myeloma. *Emerg Radiol.* 2007 Nov;14(6):425-30.
56. Alvarado Y, Apostolidou E, **Swords R**, Giles FJ. Emerging therapeutic options for Philadelphia –positive acute lymphoblastic leukemia. *Expert Opin Emerg Drugs.* 2007 Mar;12(1):165-79.
57. **Swords R**, Alvarado Y, Giles F. Novel Abl kinase inhibitors in chronic myeloid leukemia in blastic phase and Philadelphia chromosome-positive acute lymphoblastic leukemia. *Clin Lymphoma Myeloma.* 2007 Mar;7 Suppl 3:S113-9.
58. **Swords R.** Imatinib in relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukaemia: a viewpoint by Ronan Swords. *Drugs.* 2007;67(17):2655-6.
59. Apostolidou E, **Swords R**, Alvarado Y, Giles FJ. Treatment of acute lymphoblastic leukaemia : a new era. *Drugs.* 2007;67(15):2153-71.
60. **Swords R**, Bruzzi J, Giles F. Recent advances in the diagnosis and therapy of Richter's syndrome. *Med Oncol.* 2007;24(1):17-32.
61. **Swords R**, Giles F. Hairy cell leukemia. *Med Oncol.* 2007;24(1):7-15.
62. **Swords R**, Apostolidou E, Giles F. Troxacitabine in leukemia. *Hematology.* 2006

Oct;11(5):321-9.

63. Murphy PT, Quinn JP, O'Donghaile D, **Swords R**, O'Donnell JR. Myelodysplastic patients with raised percentage of hypochromic red cells have evidence of functional iron deficiency Ann Hematol. 2006 Jul;85(7):455-7.
64. **Swords R**, Nolan A, Fay M, Quinn J, O'Donnell R, Murphy PT. Treatment of refractory fludarabine induced autoimmune hemolytic anemia with the monoclonal anti-CD20 antibody rituximab. Clin Lab Haematol. 2006 Feb;28(1):57-9.
65. Molloy A., **Swords R.**, Stute N. Updates in Haematology. Hospital Doctor 2006; 12: 64-70.
66. **Swords R**, Quinn J, Fay M, O'Donnell R, Goldman J, Murphy PT. CML clonal evolution with resistance to single agent imatinib therapy. Clin Lab Haematol. 2005 Oct;27(5):347-9.
67. Hayden PJ, O'Driscoll A, Gardiner N, **Swords R**, Sargent J, Ainle FN, Fortune A, Murphy PT, Leahy M, Jackson F, Ryan M, Hennessy B, Cahill M, Crotty GM, Enright H, Conneally E, Vandenberghe E, McCann SR, Browne PV. Autologous stem cell transplantation in myeloma: the St. James's hospital e, 1997-2003 experience. Ir J Med Sci. 2005 Apr-Jun;174(2):26-32.
68. **Swords R.**, Hennessy B. Updates in Haematology. Hospital Doctor 2005;11:57-59
69. **Swords R**, Hayden PJ, Molloy K, Lawlor M, Browne PV, Murphy PT. Successful induction of molecular remission with single-agent anti-CD33 antibody (gemtuzumab ozogamicin) in chemotherapy-refractory relapse of acute myeloid leukaemia post-BMT. Eur J Haematol. 2004 Dec;73(6):450-1.
70. Murphy PT, Fay MJ, **Swords RT**, Quinn JP, O'Donnell JR. Progression of myelodysplasia during low-dose methotrexate therapy in rheumatoid arthritis. Ann Pharmacother. 2004 Nov;38(11):1969-70.
71. **Swords R**, Power D, Fay M, O'Donnell R, Murphy PT. Interstitial pneumonitis following rituximab therapy for immune thrombocytopenic purpura (ITP). Am J Hematol. 2004 Sep;77(1):103-4.
72. **Swords R**, Fay M, O'Donnell R, Murphy PT. Anagrelide-induced visual hallucinations in a patient with essential thrombocythemia. Eur J Haematol. 2004 Sep;73(3):223-4.
73. O'Connor TM, **Swords R**, O'Keefe D, McNicholas WT. Improved ventilatory function associated with relief of chest pain in a patient with Kartagener's syndrome treated by subcutaneous analgesia. Respir Med. 2004 Jul;98(7):679-81.

2. Book Chapters

1. Giles FJ, Krawczyk J, O'Dwyer M, Swords R, Freeman C. The role of inflammation in leukaemia. Adv Exp Med Biol. 2014;816:335-60

3. Presentations to Learned Societies

Poster Presentations

1. D DeAngelo, H Erba, M Marris, **R Swords**, F Anwer, J Altman, Z Hua, S Blakemore, H Faessel, B Dezube, B Medeiros. MLN4924, a Novel Investigational Inhibitor Of NEDD8-Activating Enzyme (NAE), In Adult Patients With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS): Results From Multiple Dosing Schedules In a Phase 1 Study. American Society of Hematology 2013, abstract # 143.
2. G Leclerc, S Zheng, **R Swords**, G Leclerc, J Barredo. The NEDD8 Conjugation Pathway Inhibitor MLN4924 Activates AMPK and Induces The ER Stress/UPR-Mediated Cell Death Pathway In Acute Lymphoblastic Leukemia. American Society of Hematology 2013, abstract # 1285.
3. J Lancet, A Wei, S Durrant, M Hertzberg, **R Swords**, I Lewis, B Jonas, J Cortes, G Yarranton, J Walling. A Phase I Study Of KB004, a Novel Non-Fucosylated humanized Antibody, Targeted Against The Receptor Tyrosine Kinase EphA3, In Advanced Hematologic Malignancies. American Society of Hematology 2013, abstract # 3838.
4. **Swords R**, Santini V. In elderly patients with AML, which patients should be considered fit or unfit for standard induction therapy? American Society of Hematology, 2012: 74 – 75

5. A McDonald, K Burke, F Gao, S Kuan, M Theisen, SJ Blakemore, A Berger, M Fleming, B Dezube, H Erba, B Medeiros, D DeAngelo, R Swords, S Tirrell. Pharmacodynamic Assays demonstrate NAE Pathway Inhibition Following Administration of MLN4924 in Patients with Acute Myeloid Leukemia. European Hematology Association 2012, abstract # 0084.
6. H Erba, **R Swords**, D DeAngelo, D Bixby, M Pickard, G Mulligan, S Kuan, P Smith, B Dezube, F Giles, B Medeiros. MLN4924, A Novel Investigational NEDD8-Activating Enzyme (NAE) Inhibitor in Adult Patients with Acute Myeloid Leukemia (AML) or High-Grade Myelodysplastic Syndromes (MDS): Results from a Phase I Study. European Hematology Association 2011, abstract # 0068.
7. S Langabeer, S McCarron, M Wiczorkowska, F Ringel, M Müller, D Hicks, **R Swords**, S Padmanabhan, F Giles, P Le Coutre, MF McMullin, M O'Dwyer, E Conneally. Prospective Evaluation of an Automated, Cartridge Based System for Quantification of BCR-ABL 1 Transcripts by Comparison with RQ-PCR Aligned to the International Scale: Results from the ICORG 0802 Trial. European Hematology Association 2011, abstract # 0192.
8. Eibhlin Conneally, **Ronan T Swords**, Francis J. Giles, Mary Frances McMullin, Philipp le Coutre, Stephen Langabeer, Marzena Wiczorkowska, Cliona McDowell, Brian Moulton, Karine Egan and Michael O'Dwyer. Nilotinib 300 Mg Twice Daily as First Line Treatment of Ph-Positive Chronic Myeloid Leukemia In Chronic Phase: Updated Results of the ICORG 0802 Phase 2 Study with Analysis of the GeneXpert System Versus IS BCR-ABL RQ PCR. Blood (ASH Annual Meeting Abstracts), Nov 2010; 116: 3427
9. Edgar Castillo, Raed Al-Rajabi, Devesh M. Pandya, Prakash Varadarajan, Kevin R Kelly, **Ronan Swords**, Anita Tharian, Mary K. Kraus, and Swaminathan Padmanabhan. A Pilot Study of the Combination of Nilotinib and Hyper-CVAD for Philadelphia Chromosome Positive Acute Lymphocytic Leukemia and Lymphoid Blast Crisis Chronic Myelogenous Leukemia. Blood (ASH Annual Meeting Abstracts), Nov 2010; 116: 2144.
10. S Carew, **RT Swords**, KR Kelly, PG Smith, JJ Garney, D Mahalingam, E Medina, M O'Dwyer, K Oberheu, ST Nawrocki, FJ Giles. The First-In-Class Molecule Inhibitor of NEDD8-Activating Enzyme (NAE), MLN4924, Induces Stable Disease Regression in Pre-Clinical Models of Acute Myeloid Leukemia (AML). EHA 2010.
11. **Ronan Swords**, Javier Anguita, Russell A. Higgins, Andrea Yunes, Michael Naski, Swaminathan Padmanabhan, Kevin R Kelly, Devalingam Mahalingam, Thomas Philbeck, Larry Miller, Francis J. Giles, Marsha Kinney and Andrew Brenner. A New Rotary Powered Device for Bone Marrow Aspiration and Biopsy Yields Superior Specimens with Less Pain: Results of a Randomized Clinical Study. American Society of Hematology 2010, abstract # 1529
12. Swaminathan Padmanabhan, Kevin R Kelly, Mark Heaney, Stephanie Hodges, Suzanne Chanel, Mark Frattini, **Ronan Swords**, Robert Bradley, Florentina Teofilovici, and Daniel J DeAngelo. A Phase I Study of the Potent Hsp90 Inhibitor STA-9090 Administered Twice Weekly In Subjects with Hematologic Malignancies. American Society of Hematology 2010, abstract # 2898
13. Edgar Castillo, Raed Al-Rajabi, Devesh M. Pandya, Prakash Varadarajan, Kevin R Kelly, **Ronan Swords**, Anita Tharian, Mary K. Kraus and Swaminathan Padmanabhan. Pilot Study of the Combination of Nilotinib and Hyper-CVAD for Philadelphia Chromosome Positive Acute Lymphocytic Leukemia and Lymphoid Blast Crisis Chronic Myelogenous Leukemia. American Society of Hematology 2010, abstract # 2144
14. E O'Dwyer, **R Swords**, F Giles, P LeCoutre, M McMullin, S Langabeer, S Padmanabhan, E Kent, M Parker, B Moulton, K Egan, E Conneally. Nilotinib 300mg Twice Daily is Effective and Well Tolerated as First Line Treatment of Ph+ Chronic Myeloid Leukemia in First Chronic Phase – Preliminary Results of the ICORG Phase II Study. EHA 2010.
15. **Ronan Swords**, Kevin Kelly, Ernest Medina, Devalingam Mahalingam, Steffan Nawrocki, Peter Smith., Kelly Oberhau, Michael O'Dwyer., David Rizzieri., Francis Giles., Carew Jennifer. MLN4924, A Novel First in Class Inhibitor of the NEDD8 Activating Enzyme (NAE), has Potent Activity in Pre-Clinical Models of Acute Myeloid Leukemia (AML). Fifth International Conference SUMO, Ubiquitin, UBL Proteins: Implications for Human Diseases, M.D. Anderson Cancer Center, Houston, TX, February 2010

16. **Ronan Swords**, Kevin Kelly, Ernest Medina, Devalingam Mahalingam, Steffan Nawrocki, Peter Smith., Michael O'Dwyer., David Rizzieri., Francis Giles., Carew Jennifer. MLN4924, A Novel First in Class Inhibitor of the NEDD8 Activating Enzyme (NAE), has Potent Activity in Pre-Clinical Models of Acute Myeloid Leukemia (AML). EHA 2009
17. Kevin Kelly, **Ronan Swords**., Ernest Medina, Devalingam Mahalingam, Steffan Nawrocki, Sabrina Smith., Jeffrey Ecsedy., Swaminathan Padmanabhan., Francis Giles., Carew Jennifer. The Aurora A Kinase Inhibitor MLN8237 Targets Aurora A Kinase and BCR-ABL Kinase in CML, is Effective in Imatinib Resistant T315I Mutations, and Significantly Increases the Efficacy of Nilotinib. AACR 2009
18. **Ronan Swords**, Kevin Kelly, Ernest Medina, Devalingam Mahalingam, Steffan Nawrocki, David Bearrs, Michael O'Dwyer, David Rizzieri, Gregory Berk, Frank Giles, Jennifer Carew. SGI-1776: A novel PIM Kinase Inhibitor with Potent Preclinical Activity against Acute Myeloid Leukemia. AACR 2009
19. **Ronan Swords**, Kevin Kelly, Ernest Medina, Devalingam Mahalingam, Steffan Nawrocki, Peter Smith., Kelly Oberhau, Michael O'Dwyer., David Rizzieri., Francis Giles., Carew Jennifer. MLN4924, A Novel First in Class Inhibitor of the NEDD8 Activating Enzyme (NAE), has Potent Activity in Pre-Clinical Models of Acute Myeloid Leukemia (AML). Blood (ASH Annual Meeting Abstracts), Nov 2009; 114: 1021.
20. Kevin Kelly, **Ronan Swords**., Ernest Medina, Devalingam Mahalingam, Steffan Nawrocki, Sabrina Smith., Jeffrey Ecsedy., Swaminathan Padmanabhan., Francis Giles., Carew Jennifer. The Aurora A Kinase Inhibitor MLN8237 Targets Aurora A Kinase and BCR-ABL Kinase in CML, is Effective in Imatinib Resistant T315I Mutations, and Significantly Increases the Efficacy of Nilotinib. EHA 2009
21. Kevin Kelly, **Ronan Swords**., Ernest Medina, Devalingam Mahalingam, Steffan Nawrocki, Sabrina Smith., Jeffrey Ecsedy., Swaminathan Padmanabhan., Francis Giles., Carew Jennifer. The Aurora A Kinase Inhibitor MLN8237 Targets Aurora A Kinase in AML, and Significantly Increases the Efficacy of the Standard of Care Agent Cytarabine. EHA 2009.
22. **Ronan Swords**, Kevin Kelly, Ernest Medina, Devalingam Mahalingam, Steffan Nawrocki, David Bearrs, Michael O'Dwyer, David Rizzieri, Gregory Berk, Frank Giles, Jennifer Carew. SGI-1776: A novel PIM Kinase Inhibitor with Potent Preclinical Activity against Acute Myeloid Leukemia. EHA 2009
23. **Ronan T. Swords**, Kevin R. Kelly, Devalingam Mahalingam, Stephen C. Cohen, Larry J. Miller, Thomas E. Philbeck, Jr., Sander O. Hacker, Cathy J. Spadaccini, Andrew Brenner, and Francis J. Giles Use of a New Rotary Powered Device for Bone Marrow Aspiration and Biopsy Yields Excellent Specimens Quickly and Efficiently. Blood (ASH Annual Meeting Abstracts), Nov 2009; 114: 4544.
24. Kevin R. Kelly, **Ronan T. Swords**, Devalingam Mahalingam, Steffan T. Nawrocki, Ernest Medina, Sabrina Smith, Swaminathan Padmanabhan, Jeffrey Ecsedy, Mary R Cahill, Francis J. Giles, and Jennifer S. Carew The Novel Orally Active Aurora A Kinase Inhibitor MLN8237 Is Highly Active in Preclinical Models of Acute Myeloid Leukemia and Significantly Increases the Efficacy of Cytarabine. Blood (ASH Annual Meeting Abstracts), Nov 2009; 114: 2087
25. Michael E O'Dwyer, Emma Kent, Michael Parker, **Ronan T. Swords**, Frank Giles, Philipp le Coutre, Swaminathan Padmanabhan, Brian Moulton, Mary Frances McMullin, Stephen Langabeer, Karine Egan, and Eibhlin Conneally Nilotinib 300 Mg Twice Daily Is Effective and Well Tolerated as First Line Treatment of Ph-Positive Chronic Myeloid Leukemia in Chronic Phase: Preliminary Results of the ICORG 0802 Phase 2 Study. Blood (ASH Annual Meeting Abstracts), Nov 2009; 114: 3294.
26. Kelly K., **Swords R.**, Mahalingam D., Nawrocki S., Giles F., Carew J. The Aurora A Kinase Inhibitor MLN8237 has Potent Anticancer Activity in CML and Ph+ ALL Models and Significantly Increases the Efficacy of Nilotinib. American Society of Hematology Meeting 2009
27. Sanjy Bansal, Hima Bansal, Manjeet Rao, **Ronan Swords**, Kevin Kelly, Jennifer Carew, Kelvin Lee, Frank Giles, Swaminathan Padmanabhan. WT1 interacts with the chaperone protein HSP90 and this regulates its expression. AACR 2009

28. Sanjay Bansal, Hima Bansal, Manjeet Rao, **Ronan Swords**, Kevin Kelly, Jennifer Carew, Kelvin Lee, Frank Giles, Swaminathan Padmanabhan. WT1 Downregulates Interferons Through the JAK/STAT Pathway. AACR 2009
29. Devalingam Mahalingam., Ernest Medina., **Ronan Swords.**, Kevin Kelly., Jennifer Carew., Francis Giles., Steffan Nawrocki. The combination of Sutent with the PIM Kinase Inhibitor SGI-1776 has Synergistic Activity in Pre-Clinical Models of Renal Cell Carcinoma. AACR 2009
30. J. Krawczyck., N Ansar., T Murphy., B McDonagh., **R Swords.**, T Meenaghan., P Hayden., A Hayat., M Murray., M O Dwyer. Clofarabine in the Treatment of Poor Risk Acute Myeloid Leukemia – Galway University Hospital Experience. EHA 2009 (abstract).
31. J. Krawczyck., T Murphy., **R Swords.**, T Meenaghan., M O Dwyer. Novel Treatment of Multicentric Castlemans Disease with Lenalinomide. EHA 2008 (abstract)
32. Kelly K., Steffan T. Nawrocki, Ernest Medina, Sabrina Smith, **Ronan Swords**, Kevin Kelly, Swaminathan Padmanabhan, Jeffrey Ecsedy, Francis J Giles, and Jennifer Carew. The Aurora Kinase Inhibitor MLN8237 Has Potent Anticancer Activity in CML and Ph+ ALL Models and Significantly Increases the Efficacy of Nilotinib. Blood (ASH Annual Meeting Abstracts), Nov 2008; 112: 3198.
33. **Swords R.**, O'Dalaigh A., Barry D., Morris CPM., Hennessy B. Synergistic Efficacy of PUVA and Bexarotene in a Patient with Cutaneous T-Cell Lymphoma. Irish Molecular Medicine Society Meeting, Dublin, 2006.
34. Slaby J., **Swords R.**, Vandenberghe E. A Single Centre Experience in the Treatment of Burkitt Lymphoma. Haematology Association of Ireland, Cork, 2006.
35. **Swords R.**, McDonagh B., Tan T., Ooi M., Murray M., Egan E., O'Dwyer M. Diagnosis and Management of Extramedullary Granulocytic Sarcoma – A Case Study. Haematology Association of Ireland, Belfast, Ireland, Nov. 2005
36. **Swords R.**, McLaughlin B., Barr C., Kelly J., Hennessy B. The Role of Blood Stock Inventory Management in Reducing Wastage and Outdate Rates in a Peripheral Hospital – A Clinical Audit. Haematology Association of Ireland, Belfast, Ireland, Nov. 2005
37. **Swords R.**, Hawkins F., Tan T., Ooi M., Murray M., Egan E., O'Dwyer M. High Dose Therapy and Peripheral Blood Stem Cell Transplant for Primary Refractory Hodgkins Disease – A Case Presentation. Haematology Association of Ireland, Belfast, Ireland, Nov. 2005
38. **Swords R.**, O'Dalaigh A., Vandenberghe E., Hennessy B. Occupational Exposure to Pesticides as a Risk Factor for Aggressive Non-Hodgkins Lymphoma – A Case Study. Haematology Association of Ireland, Belfast, Ireland, Nov. 2005
39. Murphy P.T., O'Sullivan V., **Swords R.**, Quinn J., Fay M., O'Regan K., O'Donnell R. Surface Expression of VEGF by CLL Cells Correlates with Intracellular BCL-2 and KI67 Expression and Suggests that VEGF may Contribute to Growth and Survival of CLL Cells in an Autocrine Manner European Haematology Association, Stockholm, Sweden, 2005
40. Murphy P.T., Mylan C., Quinn J., **Swords R.**, Fay M., O'Regan K., O'Donnell R. In Myeloma, Surface Expression of CD130 Correlates with Surface Expression of VEGF and with Intracellular Levels of the Proliferation Marker KI67. European Haematology Association, Stockholm, Sweden, 2005
41. Hayden P.J., O'Driscoll A., Gardiner N., **Swords R.**, Sargent J., Ni Ainghaile F., Fortune A., Murphy P.T., Leahy M., Jackson F., Ryan M., Hennessy B., Cahill M., Crotty G., Enright H., McCann S., Browne P.V. Autologous Stem Cell Transplantation in Myeloma 1997 - 2003 : The St. James' Hospital Experience. Haematology Association of Ireland, Galway, Ireland, Nov. 2004.
42. **Swords R.**, O'Dalaigh A., Barry D., Morris CPM., Hennessy B. Synergistic Efficacy of PUVA and Bexarotene in a Patient with Cutaneous T-Cell Lymphoma. Haematology Association of Ireland, Galway, Ireland, Nov. 2004.
43. **Swords R.**, Power D., Fay M., O'Donnell R., Murphy P.T. Clonal Evolution with Double Philadelphia Chromosome Positivity in a Patient with Chronic Myeloid Leukaemia – An Unusual Finding. Haematology Association of Ireland, Tullamore, Ireland, Nov. 2003.
44. **Swords R.**, Quinn J., Fay M., Flanagan A., O'Donnell R., Murphy P.T. Study of the Possible Proangiogenic Effects of Recombinant Erythropoietin Therapy in Patients with

Haematological Malignancies. Haematology Association of Ireland, Tullamore, Ireland, Nov. 2003.

Oral Presentations

1. First-in-class NAE inhibitor pevonedistat (MLN4924), in combination with azacitidine for acute myeloid leukemia (AML) patients considered unfit for conventional chemotherapy: Results from the C15009 trial. **European Hematology Association, Milan, 2014.**
2. Leukemia, Myelodysplasia, Stem Cell Transplantation: Poster Highlights Session. **Session Chair. American Society of Clinical Oncology, Chicago, 2014.**
3. Chronic Myeloid Leukemia: Therapy and Prognosis. **Session Chair. American Society of Hematology, New Orleans, 2013.**
4. Disruption of NEDD8 Protein Conjugation: A Novel Therapeutic Strategy for the Myeloid Neoplasms. *Grand Rounds Invited Speaker, Robert H Lurie Comprehensive Cancer Center, Northwestern University, Chicago, 2013*
5. Novel Prognostic Markers in Acute Leukemia. **European Hematology Association, Amsterdam, 2012.**
6. Managing the Myeloid Leukemias: New Targets and New Drugs. *Grand Rounds, Invited Speaker, Sylvester Comprehensive Cancer Center, Sylvester Comprehensive Cancer Center, Miami, 2011*
7. Acute Myeloid Leukemia: Blasts, Auer Rods, Chromosomes and the Titanic. *Grand Rounds, University of Texas health science Center, San Antonio, Texas, 2011*
8. The Novel, Investigational NEDD8-Activating Enzyme Inhibitor MLN4924 In Adult Patients with Acute Myeloid Leukemia (AML) or High-Grade Myelodysplastic Syndromes (MDS): A Phase 1 Study Blood. **American Society of Hematology, San Diego, 2010.**
9. Treatment Strategies for Philadelphia Chromosome Positive Chronic Myeloid Leukemia. *Novartis Promotional Speaking Engagement, Dallas, August 2010.*
10. Treatment Strategies for Philadelphia Chromosome Positive Chronic Myeloid Leukemia. *Novartis Promotional Speaking Engagement, Tyler, August 2010.*
11. Treatment Strategies for Philadelphia Chromosome Positive Chronic Myeloid Leukemia. *Novartis Promotional Speaking Engagement, Laredo, July 2010.*
12. Efficacy of First-Line TKI therapy. *CML Opinion Leader Meeting, San Antonio, May 2010*
13. Chronic Phase CML Clinical cases: Optimizing Response and Practical Management of Side Effects of Imatinib *CML Opinion Leader Meeting, San Antonio, May 2010*
14. Nilotinib in advanced phase CML. *CML Opinion Leader Meeting, San Antonio, May 2010.*
15. Acute Myeloid Leukemia – Updates from the American Society of Hematology Meeting 2008. *Texas Blood Forum, Lymphoma and Leukemia Society, Dallas, Feb 2009.*
16. Chronic Myeloid Leukemia – What do I do? When do I do it? Why do I do it? *The Duke Debates, Duke University, Ashville, April 2009.*
17. Efficacy of First-Line Imatinib Therapy – Chronic Phase Chronic Myeloid Leukemia. *CML Opinion Leader Meeting, San Antonio, December 2009.*
18. Response Evaluation of First-Line Tyrosine Kinase Inhibitor Therapy. *CML Opinion Leader Meeting, San Antonio, December 2009.*
19. Resistance: Is it or isn't it? *CML Opinion Leader Meeting, San Antonio, December 2009.*
20. New Agents in Chronic Myeloid Leukemia. *CML Opinion Leader Meeting, San Antonio, December 2009.*
21. Efficacy of Frontline Tyrosine Kinase Inhibitor Therapy. *Medical Grand Rounds, Cancer Care Centers of South Texas, Kerrville, Texas, July 2009.*
22. New Agents in Leukemia – Updates from ASCO 2009. *American Academy of Physician Assistants Annual Meeting, Boston, May 2009.*
23. Advancement of Patient Care in Philadelphia Chromosome Positive Chronic Myeloid Leukemia. *Chronic Myeloid Leukemia Pocket Meeting, Las Vegas, October 2009*

V. PROFESSIONAL

MEMBERSHIP OF LEARNED SOCIETIES

Royal College of Physicians of Ireland (RCPI)
Royal College of Pathologists, London, UK. (RCPATH, UK)
Haematology Association of Ireland (HAI)
American Society of Hematology (ASH)
South West Oncology Group (SWOG)
American Society of Clinical Oncology (ASCO)
Developmental Therapeutics Consortium (DTC)

PROFESSIONAL AND SCIENTIFIC SERVICE

Manuscript reviewer: American Journal of Hematology
Drugs
Leukemia
Clinical Cancer Research
Hematology
Expert Opinion on Therapeutic Targets

Membership of editorial boards: Leukemia Research Reports

Grant reviewer: Israeli Science Foundation (ISF)
Cancer Therapy and Research Center (CTRC)
Association for International Cancer Research (AICR)
American Cancer Society (ACS)

AWARDS

FECS/AACR/ASCO joint "Methods in Clinical Cancer Research" scholarship, Flims, Switzerland.
June 2007
FECS/AACR/ASCO Methods in Cancer Biology Workshop scholarship, Aspen, Colorado.
June 2009
Oppenheimer Outstanding Researcher of the year award (\$50,000 research bursary). August
2009
ASH scholarship award. Clinical Research Training Institute (CRTI) mentored training award.
June 2011
Womens Cancer Association Researcher of the Year Award 2014.

GRANTS/CONTRACTS

Industry (Completed)

1. Takeda Pharmaceuticals
A Phase I Dose Escalating Study of MLN4924, a Novel Inhibitor of the NEDD8 Activating Inhibitor (NAE), in Patients with Acute Myeloid Leukemia and Advanced Myelodysplasia.
Role: PI
Direct Costs: \$53,520
2. Nerviano Pharmaceuticals

A Phase I Study of NMS-1116354 in Adult Patients with Hematologic Malignancies

Role: PI

Direct Costs: \$48,980

3. Roche Pharmaceuticals

A Phase I Study of R7119, a Novel MDM2 Inhibitor, in Patients with Advanced Refractory Acute and Chronic Myeloproliferative Disorders

Role: PI

Direct Costs: \$68,920

4. CytRx Pharmaceuticals

Phase II Multicenter Study of Tamibarotene in Relapsed Acute Promyelocytic Leukemia (APL)

Role: PI

Direct Costs: \$23,340

5. Inovio

A Phase I Dose Escalating Study of the Recombinant Protein WT1, in Older Patients with AML in CR1

Role: PI

Direct Costs: \$34,800

Industry (active)

1. KaloBios

Study of the Anti-EphA3 Monoclonal Antibody KB004 in Subjects with EphA3 expressing Hematologic Malignancies

Role: PI

Direct Costs: \$65,800

2. GSK

An Randomized Placebo Controlled Dose Finding Study to Assess the Safety and Efficacy of the Oral Thrombopoietin Receptor Eltrombopag, Administered to Subjects with Acute Myeloid Leukemia (AML) Receiving Induction Chemotherapy.

Role: PI

Direct Costs: \$12,300

3. Agios

A Phase I, Multicenter, Open Label, Dose Escalation, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-221 in Subjects with Advanced Hematologic Malignancies with an IDH2 Mutation

Role: PI

Direct Costs: \$11,300

5. Takeda Pharmaceuticals

A Phase IB, Open Label, Dose Escalation Study of MLN4924 Plus Azacitidine in Treatment Naïve Patients with Acute Myeloid Leukemia Who are 60 Years or Older

Role: PI

Direct Costs: \$83,450

Investigator Initiated Trials (completed)

1. Irish Cooperative Oncology Group (ICORG)

A Phase II Open Label Multicenter Study to Evaluate The Efficacy and Safety of Nilotinib at a Dose of 300mg BID in the Upfront management of Chronic Myeloid Leukemia (CML) in First Chronic Phase (CP)

Role: PI
Direct Costs

Investigator Initiated Trials (active)

1. Takeda Pharmaceuticals

A Phase 1 PK and PD Study of Escalating Doses of MLN4924 in Combination with a Fixed Dose of Cytarabine in Adult Patients with AML and High Risk MDS.

Total Direct Costs: \$230,223.00

Role: PI

2. Sylvester Comprehensive Cancer Center Institutional Funding

A Phase I Dose Escalation Study of ATRA combined with Tranylcypromine (TCP) for Patients with Relapsed or Refractory Myelodysplastic Syndromes (MDS) or Acute Myeloid Leukemia (AML).

Total Direct Costs: \$100,000

Role: PI

NIH Awards (active)

NIH/K12

Targeted Approaches in Myeloid Malignancies.

Total Direct Costs: \$650,000

Role: PI

Foundation Funding (active)

1. Gabrielle's Angel Foundation

Targeting NEDD8 protein conjugation: a novel therapeutic strategy for acute lymphoblastic leukemia. Gabrielle's Angel Foundation

Total Costs: \$25,000

Role: PI

2. Womens Cancer Association

A new indication for an old drug: exploring sodium salicylate activity in patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML).

Role: PI

Total Direct Costs: \$40,000

VI. TEACHING

2009 – present: teaching medical students, residents, and hematology/oncology at attending level

2012 – present: Member of Hematology/Oncology fellowship admissions committee (SCCC)

2012 – present: Member of Pathology fellowship admissions committee (SCCC)

2013 – present: Doctoral thesis advisory committee, Shuhua Zheng, University of Miami Cancer Biology Program.